Human Vaccines & Immunotherapeutics最新文献_第9页

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines. 新冠肺炎mRNA疫苗BNT162b2在灭活SARS-CoV-2病毒疫苗后作为异源加强剂的疫苗有效性的证据合成和汇总分析。

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-31 Epub Date: 2023-02-01 DOI: 10.1080/21645515.2023.2165856

Moe H Kyaw, Julia Spinardi, Ling Zhang, Helen May Lin Oh, Amit Srivastava

{"title":"Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines.","authors":"Moe H Kyaw, Julia Spinardi, Ling Zhang, Helen May Lin Oh, Amit Srivastava","doi":"10.1080/21645515.2023.2165856","DOIUrl":"10.1080/21645515.2023.2165856","url":null,"abstract":"Introduction of primary COVID-19 vaccination has helped reduce severe disease and death caused by SARS-CoV-2 infection. Understanding the protection conferred by heterologous booster regimens informs alternative vaccination strategies that enable programmatic resilience and can catalyze vaccine confidence and coverage. Inactivated SARS-CoV-2 vaccines are among the most widely used vaccines worldwide. This review synthesizes the available evidence identified as of May 26, 2022, on the safety, immunogenicity, and effectiveness of a heterologous BNT162b2 (Pfizer-BioNTech) mRNA vaccine booster dose after an inactivated SARS-CoV-2 vaccine primary series, to help protect against COVID-19. Evidence showed that the heterologous BNT16b2 mRNA vaccine booster enhances immunogenicity and improves vaccine effectiveness against COVID-19, and no new safety concerns were identified with heterologous inactivated primary series with mRNA booster combinations.","PeriodicalId":13058,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"19 1","pages":"2165856"},"PeriodicalIF":4.8,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d7/49/KHVI_19_2165856.PMC9980688.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10286783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis. 免疫检查点抑制剂作为非小细胞肺癌的一线治疗:一项系统评价和荟萃分析

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-31 Epub Date: 2023-01-30 DOI: 10.1080/21645515.2023.2169531

Yu Lu, Xiaoyan Zhang, Jiyu Ning, Manyan Zhang

{"title":"Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis.","authors":"Yu Lu, Xiaoyan Zhang, Jiyu Ning, Manyan Zhang","doi":"10.1080/21645515.2023.2169531","DOIUrl":"10.1080/21645515.2023.2169531","url":null,"abstract":"Recently, immune checkpoint inhibitors (ICIs) present promising application prospects in treating non-small cell lung cancer (NSCLC). This study aimed to investigate optimal treatment strategy by comparing the first-line treatment strategies with ICIs in NSCLC. We retrieved relevant studies on first-line therapy of NSCLC with ICIs. Primary outcomes were overall survival (OS) and progression-free survival (PFS). Secondary outcomes were treatment-related serious adverse events (tr-SAEs) with grade 3 or higher and objective response rate (ORR). We also conducted a Bayesian network meta-analysis. We included 14 studies involving 7,823 patients and compared seven different interventions. In PD-L1 nonselective NSCLC, nivolumab+ipilimumab had good PFS and ORR, pembrolizumab significantly prolonged OS, and nivolumab had the fewest adverse events (AEs). For PD-L1-positive patients, nivolumab remarkably prolonged OS. For those with negative PD-L1, nivolumab+ipilimumab also showed an advantage. In addition, nivolumab+ipilimumab significantly prolonged the PFS in both PD-L1-negative and -positive patients. For patients with PD-L1 tumor proportion score (TPS) within 1-49%, atezolizumab+chemotherapy remarkably prolonged PFS and OS. For those with PD-L1 TPS ≥50%, pembrolizumab prolonged OS and atezolizumab+chemotherapy significantly prolonged PFS. Nivolumab combined with ipilimumab showed advantages in OS, PFS and ORR in most patients. Nivolumab+ipilimumab may be the optimal first-line therapy for NSCLC.","PeriodicalId":13058,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"19 1","pages":"2169531"},"PeriodicalIF":4.8,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/22/00/KHVI_19_2169531.PMC10038046.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9929646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Epidemiology of human papillomavirus on condyloma acuminatum in Shandong Province，China. 山东省尖锐湿疣人乳头瘤病毒流行病学分析。

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-31 Epub Date: 2023-03-15 DOI: 10.1080/21645515.2023.2170662

Haowen Yuan, Renpeng Li, Jian Lv, Guipeng Yi, Xihong Sun, Na Zhao, Fengjun Zhao, Aiqiang Xu, Zengqiang Kou, Hongling Wen

{"title":"Epidemiology of human papillomavirus on condyloma acuminatum in Shandong Province，China.","authors":"Haowen Yuan, Renpeng Li, Jian Lv, Guipeng Yi, Xihong Sun, Na Zhao, Fengjun Zhao, Aiqiang Xu, Zengqiang Kou, Hongling Wen","doi":"10.1080/21645515.2023.2170662","DOIUrl":"10.1080/21645515.2023.2170662","url":null,"abstract":"Condyloma acuminatum (CA) is a sexually transmitted disease (STD) caused by human papillomavirus (HPV) infection. It is important to study the prevalence and distribution of HPV genotypes before implementing the HPV vaccination program. Therefore, the aim of this study was to evaluate the epidemiological characteristics of CA cases and the distribution of HPV genotypes in Shandong Province, China. One-to-one questionnaire surveys were conducted on all patients diagnosed with CA in sentinel hospitals from Shandong Province, China. HPV genotypes were determined using the polymerase chain reaction (PCR)-reverse dot blot hybridization method. The study enrolled 1185 patients (870 males and 315 females) and found that CA patients are mainly males and sexually active people between the ages of 20 and 40. Recurrence occurred in 34.7% patients. Among the 880 CA patients who underwent HPV typing, the HPV test positivity rate was 91.4%. In these cases, low-risk (LR) HPV infection was predominant, with an infection rate of 91.3%, while high-risk (HR) HPV genotypes were found in 53.5% patients. The most frequent HPV genotypes encountered were HPV6 (57.8%), HPV11 (37.2%), HPV16 (13.7%), and HPV42 (10.3%). HPV6 and/or HPV11 are the main infections in all patients, and more than half of the patients are coinfected with HR-HPV. However, unlike other regions, HPV42 has a higher prevalence rate among CA patients in Shandong Province and is a nonvaccine HPV genotype. Therefore, regular HPV typing helps to understand the characteristics of specific genotypes and the choice of the best type for vaccine coverage.","PeriodicalId":13058,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"19 1","pages":"2170662"},"PeriodicalIF":4.8,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/94/d2/KHVI_19_2170662.PMC10064924.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9348221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vaccine effectiveness of recombinant and standard dose influenza vaccines against outpatient illness during 2018-2019 and 2019-2020 calculated using a retrospective test-negative design. 使用回顾性阴性设计计算2018-2019年和2019-2020年期间重组和标准剂量流感疫苗对门诊疾病的疫苗有效性。

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-31 Epub Date: 2023-02-21 DOI: 10.1080/21645515.2023.2177461

Richard K Zimmerman, Klancie Dauer, Lloyd Clarke, Mary Patricia Nowalk, Jonathan M Raviotta, G K Balasubramani

{"title":"Vaccine effectiveness of recombinant and standard dose influenza vaccines against outpatient illness during 2018-2019 and 2019-2020 calculated using a retrospective test-negative design.","authors":"Richard K Zimmerman, Klancie Dauer, Lloyd Clarke, Mary Patricia Nowalk, Jonathan M Raviotta, G K Balasubramani","doi":"10.1080/21645515.2023.2177461","DOIUrl":"10.1080/21645515.2023.2177461","url":null,"abstract":"Newer influenza vaccine formulations have entered the market, but real-world effectiveness studies are not widely conducted until there is sufficient uptake. We conducted a retrospective test-negative case-control study to determine relative vaccine effectiveness (rVE) of recombinant influenza vaccine or RIV4, compared with standard dose vaccines (SD) in a health system with significant RIV4 uptake. Using the electronic medical record (EMR) and the Pennsylvania state immunization registry to confirm influenza vaccination, VE against outpatient medically attended visits was calculated. Immunocompetent outpatients ages 18-64 years seen in hospital-based clinics or emergency departments who were tested for influenza using reverse transcription polymerase chain reaction (RT-PCR) assays during the 2018-2019 and 2019-2020 influenza seasons were included. Propensity scores with inverse probability weighting were used to adjust for potential confounders and determine rVE. Among this mostly white and female cohort of 5,515 individuals, 510 were vaccinated with RIV4 and 557 were vaccinated with SD, with the balance of 4,448 (81%) being unvaccinated. Adjusted influenza VE estimates were 37% overall (95% CI = 27, 46), 40% (95% CI = 25, 51) for RIV4 and 35% (95% CI = 20, 47) for standard dose vaccines. Overall, rVE of RIV4 compared to SD was not significantly higher (11%; 95% CI = -20, 33). Influenza vaccines were moderately protective against medically attended outpatient influenza during the 2018-2019 and 2019-2020 seasons. Although the point estimates are higher for RIV4, the large confidence intervals around VE estimates suggest this study was underpowered to detect significant rVE of individual vaccine formulations.","PeriodicalId":13058,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"19 1","pages":"2177461"},"PeriodicalIF":4.8,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/be/50/KHVI_19_2177461.PMC10026862.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9678274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Progression of hemolysis in a patient with hereditary spherocytosis after the second dose of COVID-19 mRNA vaccine. 遗传性球形红细胞增多症患者第二次接种COVID-19 mRNA疫苗后溶血的进展

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-31 Epub Date: 2023-01-10 DOI: 10.1080/21645515.2023.2165381

Jun Nomura, Masafumi Seki, Syori Abe, Tadahiro Kobayashi, Yoko Okitsu, Noriko Fukuhara, Shinichiro Takahashi, Hideo Harigae, Junichi Kameoka

引用次数: 0

The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review. 不同国家SARS-CoV-2感染人群中基因组变体的相对流行率:一项系统综述

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-31 DOI: 10.1080/21645515.2023.2212568

Aparajita Sarkar, Sara Omar, Aya Alshareef, Kareem Fanous, Shaunak Sarker, Hasan Alroobi, Fahad Zamir, Mahmoud Yousef, Dalia Zakaria

{"title":"The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review.","authors":"Aparajita Sarkar, Sara Omar, Aya Alshareef, Kareem Fanous, Shaunak Sarker, Hasan Alroobi, Fahad Zamir, Mahmoud Yousef, Dalia Zakaria","doi":"10.1080/21645515.2023.2212568","DOIUrl":"10.1080/21645515.2023.2212568","url":null,"abstract":"The Omicron variant of SARS-CoV-2 was detected in October 2021 and exhibited high transmissibility, immune evasion, and reduced severity when compared to the earlier variants. The lesser vaccine effectiveness against Omicron and its reduced severity created vaccination hesitancy among the public. This review compiled data reporting the relative prevalence of Omicron as compared to the early variants to give an insight into the existing variants, which may shape the decisions regarding the targets of the newly developed vaccines. Complied data revealed more than 90% prevalence within the infected cohorts in some countries. The BA.1 subvariant predominated over the BA.2 during the early stages of the Omicron wave. Moreover, BA.4/BA.5 subvariants were detected in South Africa, USA and Italy between October 2021 and April 2022. It is therefore important to develop vaccines that protect against Omicron as well as the early variants, which are known to cause more severe complications.","PeriodicalId":13058,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"19 1","pages":"2212568"},"PeriodicalIF":4.8,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d4/ec/KHVI_19_2212568.PMC10234134.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9573222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer. 预测晚期胰腺癌患者对PD-1抑制剂反应的生物标志物

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-31 Epub Date: 2023-02-21 DOI: 10.1080/21645515.2023.2178791

Xin Qiu, Zhan Shi, Fan Tong, Changchang Lu, Yahui Zhu, Qiaoli Wang, Qing Gu, Xiaoping Qian, Fanyan Meng, Baorui Liu, Juan Du

{"title":"Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer.","authors":"Xin Qiu, Zhan Shi, Fan Tong, Changchang Lu, Yahui Zhu, Qiaoli Wang, Qing Gu, Xiaoping Qian, Fanyan Meng, Baorui Liu, Juan Du","doi":"10.1080/21645515.2023.2178791","DOIUrl":"10.1080/21645515.2023.2178791","url":null,"abstract":"Pancreatic cancer is among the most lethal malignant neoplasms, and few patients with pancreatic cancer benefit from immunotherapy. We retrospectively analyzed advanced pancreatic cancer patients who received PD-1 inhibitor-based combination therapies during 2019-2021 in our institution. The clinical characteristics and peripheral blood inflammatory markers (neutrophil-to-lymphocyte ratio [NLR], platelet-to-lymphocyte ratio [PLR], lymphocyte-to-monocyte ratio [LMR], and lactate dehydrogenase [LDH]) were collected at baseline. Chi-squared and Fisher's exact tests were used to evaluate relationships between the above parameters and tumor response. Cox regression analyses were employed to assess the effects of baseline factors on patients' survival and immune-related adverse events (irAEs). Overall, 67 patients who received at least two cycles of PD-1 inhibitor were considered evaluable. A lower NLR was independent predictor for objective response rate (38.1% vs. 15.2%, P = .037) and disease control rate (81.0% vs. 52.2%, P = .032). In our study population, patients with lower LDH had superior progression-free survival (PFS) and overall survival(OS) (mPFS, 5.4 vs. 2.8 months, P < .001; mOS, 13.3 vs. 3.6 months, P < .001). Liver metastasis was verified to be a negative prognostic factor for PFS (2.4 vs. 7.8 months, P < .001) and OS (5.7 vs. 18.0 months, P < .001). The most common irAEs were hypothyroidism (13.4%) and rash (10.5%). Our study demonstrated that the pretreatment inflammatory markers were independent predictors for tumor response, and the baseline LDH level and liver metastasis were potential prognostic markers of survival in patients with pancreatic cancer treated with PD-1 inhibitors.","PeriodicalId":13058,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"19 1","pages":"2178791"},"PeriodicalIF":4.8,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dc/54/KHVI_19_2178791.PMC10026926.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9203465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Penta- and hexavalent vaccination of extremely and very-to-moderate preterm infants born at less than 34 weeks and/or under 1500 g: A systematic literature review. 34周以下和/或1500克以下出生的极重度和极中度早产儿的五价和六价疫苗接种：一项系统文献综述。

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-31 DOI: 10.1080/21645515.2023.2191575

Markus Knuf, Marie-Laure Charkaluk, Phung Nguyen The Nguyen, Ignacio Salamanca de la Cueva, Petra Köbrunner, Lauren Mason, Maurine Duchenne, Valérie Berlaimont

{"title":"Penta- and hexavalent vaccination of extremely and very-to-moderate preterm infants born at less than 34 weeks and/or under 1500 g: A systematic literature review.","authors":"Markus Knuf, Marie-Laure Charkaluk, Phung Nguyen The Nguyen, Ignacio Salamanca de la Cueva, Petra Köbrunner, Lauren Mason, Maurine Duchenne, Valérie Berlaimont","doi":"10.1080/21645515.2023.2191575","DOIUrl":"10.1080/21645515.2023.2191575","url":null,"abstract":"Debate regarding vaccinating high-risk infants with penta- and hexavalent vaccines persists, despite their good immunogenicity and acceptable safety profile in healthy full-term infants. We report the findings of a systematic literature search that aimed to present data on the immunogenicity, efficacy, effectiveness, safety, impact, compliance and completion of penta- and hexavalent vaccination in high-risk infants, including premature newborns. Data from the 14 studies included in the review showed that the immunogenicity and the safety profile of penta- and hexavalent vaccines in preterm infants was generally similar to those seen in full-term infants, with the exception of an increase in cardiorespiratory adverse events such as apnea, bradycardia and desaturation following vaccination in preterm infants. Despite recommendations of vaccinating preterm infants according to their actual age, and the relatively high completion rate of the primary immunization schedule, vaccination was often delayed, increasing the vulnerability of this high-risk population to vaccine-preventable diseases.","PeriodicalId":13058,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"19 1","pages":"2191575"},"PeriodicalIF":4.8,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/09/b3/KHVI_19_2191575.PMC10120554.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9930496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review. 与Delta和其他变体相比，预Omicron COVID-19疫苗在减少感染、住院、严重程度和死亡率方面的有效性:一项系统综述。

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-31 Epub Date: 2023-03-13 DOI: 10.1080/21645515.2023.2167410

Pradipta Paul, Ahmed El-Naas, Omar Hamad, Mohammad A Salameh, Nada Mhaimeed, Ibrahim Laswi, Ali A Abdelati, Jamal AlAnni, Bushra Khanjar, Dana Al-Ali, Krishnadev V Pillai, Abdallah Elshafeey, Hasan Alroobi, Zain Burney, Omar Mhaimeed, Mohammad Bhatti, Pratyaksha Sinha, Muna Almasri, Ahmed Aly, Khalifa Bshesh, Reem Chamseddine, Omar Khalil, Ashton D'Souza, Thanu Shree, Narjis Mhaimeed, Lina Yagan, Dalia Zakaria

{"title":"Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review.","authors":"Pradipta Paul, Ahmed El-Naas, Omar Hamad, Mohammad A Salameh, Nada Mhaimeed, Ibrahim Laswi, Ali A Abdelati, Jamal AlAnni, Bushra Khanjar, Dana Al-Ali, Krishnadev V Pillai, Abdallah Elshafeey, Hasan Alroobi, Zain Burney, Omar Mhaimeed, Mohammad Bhatti, Pratyaksha Sinha, Muna Almasri, Ahmed Aly, Khalifa Bshesh, Reem Chamseddine, Omar Khalil, Ashton D'Souza, Thanu Shree, Narjis Mhaimeed, Lina Yagan, Dalia Zakaria","doi":"10.1080/21645515.2023.2167410","DOIUrl":"10.1080/21645515.2023.2167410","url":null,"abstract":"Despite widespread mass rollout programs, the rapid spread of the SARS-CoV-2 Omicron variant called into question the effectiveness of the existing vaccines against infection, hospitalization, severity, and mortality compared to previous variants. This systematic review summarizes and compares the effectiveness of the COVID-19 vaccines, with respect to the above outcomes in adults, children, and adolescents. A comprehensive literature search was undertaken on several databases. Only 51 studies met our inclusion criteria, revealing that the protection from primary vaccination against Omicron infection is inferior to protection against Delta and Alpha infections and wanes faster over time. However, mRNA vaccine boosters were reported to reestablish effectiveness, although to a lower extent against Omicron. Nonetheless, primary vaccination was shown to preserve strong protection against Omicron-associated hospitalization, severity, and death, even months after last dose. However, boosters provide more robust and longer-lasting protection against hospitalizations due to Omicron as compared to only primary series.","PeriodicalId":13058,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"19 1","pages":"2167410"},"PeriodicalIF":4.8,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ec/3b/KHVI_19_2167410.PMC10054360.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9210285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preclinical safety evaluation of a bivalent inactivated EV71-CA16 vaccine in mice immunized intradermally. 皮内免疫小鼠双价灭活疫苗EV71-CA16的临床前安全性评价

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-31 DOI: 10.1080/21645515.2023.2209472

Yun Liao, Qinfang Jiang, Xinqian Huo, Li Yu, Jinling Yang, Heng Zhao, Dandan Li, Xingli Xu, Guorun Jiang, Caixing Zhang, Cong Li, Yun Li, Ying Zhang, Mingxiang Shao, Baofeng Liu, Lianzhong Shen, Shengtao Fan, Qihan Li

{"title":"Preclinical safety evaluation of a bivalent inactivated EV71-CA16 vaccine in mice immunized intradermally.","authors":"Yun Liao, Qinfang Jiang, Xinqian Huo, Li Yu, Jinling Yang, Heng Zhao, Dandan Li, Xingli Xu, Guorun Jiang, Caixing Zhang, Cong Li, Yun Li, Ying Zhang, Mingxiang Shao, Baofeng Liu, Lianzhong Shen, Shengtao Fan, Qihan Li","doi":"10.1080/21645515.2023.2209472","DOIUrl":"10.1080/21645515.2023.2209472","url":null,"abstract":"Hand, foot and mouth disease is a common acute viral infectious disease that poses a serious threat to the life and health of young children. With the development of an effective inactivated EV71 vaccine, CA16 has become the main pathogen causing HFMD. Effective and safe vaccines against this disease are urgently needed. In our previous study, a bivalent inactivated vaccine was shown to have good immunogenicity and to induce neutralizing antibodies in mice and monkeys. Repeated administration toxicity is a critical safety test in the preclinical evaluation of vaccines. In this study, BALB/c mice were used to evaluate the toxicity of the bivalent vaccine after multiple intradermal administrations. Clinical observation was performed daily, and body weight, food intake, hematological characteristics, serum biochemical parameters, antinuclear antibodies, CD4+/CD8a+ T-cell proportions, bone marrow smear results and pathology results were recorded. The results showed that there was no significant change at the injection site and no adverse reactions related to the vaccine. The bivalent inactivated EV71-CA16 vaccine exhibits good safety in mice, and these results provide a sufficient basis for further clinical trials.","PeriodicalId":13058,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"19 1","pages":"2209472"},"PeriodicalIF":4.8,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7b/fb/KHVI_19_2209472.PMC10208166.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9514112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0